Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 248

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 248
---
 Lebanon. Since the war broke
out, our operations have not been adversely affected by this situation, and we have not experienced disruptions to our development. However,
the intensity and duration of Israel’s current war against Hamas and Hezbollah is difficult to predict at this stage, as are such
war’s economic implications on the Company’s business and operations and on Israel’s economy in general. The Company
continues to monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or
judgments impacting its financial statements as appropriate.

| NOTE 2: | SIGNIFICANT ACCOUNTING POLICIES |

| a. | Unaudited interim condensed financial statements: |

The accompanying interim condensed balance
sheet as of June 30, 2024, the interim condensed statements of comprehensive loss, temporary equity and shareholders’ deficit,
and cash flows for the six months ended June 30, 2024, and 2023, and the related notes to such interim condensed financial statements
are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting
principles (“U.S. GAAP”) and are presented in accordance with the rules and regulations of the U.S. Securities and Exchange
Commission (“SEC”) and do not include all disclosures normally required in annual financial statements prepared in accordance
with U.S. GAAP.

In management’s opinion, the unaudited
interim condensed financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments,
which include only normal recurring adjustments necessary for the fair presentation of the Company’s financial position as of June
30, 2024, and the Company’s results of operations and cash flows for the six months ended June 30, 2024, and 2023. The results
for the six months ended June 30, 2024, are not necessarily indicative of the results to be expected for the full year ending December
31, 2024, or any other future interim or annual periods. These unaudited interim condensed financial statements should be read in conjunction
with the audited financial statements and accompanying notes as of and for the year ended December 31, 2023. The significant accounting
policies applied in the annual financial statements of the Company as of and for the year ended December 31, 2023 are applied consistently
in these interim condensed financial statements.

<div align='center'>F-7</div>

REGENTIS